Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer

摘要：

The availability of biologicals, such as anti-EFGR and anti-VEGF antibodies in combination with chemotherapy (ChT), has improved prognosis of metastatic colorectal cancer (mCRC).

所属期刊栏目：7

资助基金：This work was supported in part by grants from the Spanish Government, Ministerio de Economía y CompetitividadFIS PI12/02767 and PI15/02180 to AC;Generalitat ValencianaPROMETEO 2013-005 to AC;CIBERONC

在线出版日期：2019-07-18（万方平台首次上网日期，不代表论文的发表时间）

页数：共4页

页码：395-398